2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride

• ChemBase编号: 73296
• 分子式: C13H21ClN6O4
• 平均质量: 360.79664
• 单一同位素质量: 360.13128086
• SMILES: [nH]1c(nc2c(c1=O)ncn2COCCOC(=O)[C@H](C(C)C)N)N.Cl
• Canonical SMILES: CC([C@@H](C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O)N)C.Cl
• InChI: InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1
• InChIKey: ZCDDBUOENGJMLV-QRPNPIFTSA-N

名称和登记号

名称

• IUPAC标准名: 2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride
• IUPAC传统名: valacyclovir hydrochloride; 2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride
• 别名: Valaciclovir HCl; Valtrex; Zelitrex; Valaciclovir Hydrochloride; (S)-2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)ethyl 2-amino-3-methylbutanoate hydrochloride

登记号

• CAS号: 124832-26-4; 124832-27-5
• PubChem SID: 162038216
• PubChem CID: 60772

理论计算性质

• Acid pKa: 10.160745
• 质子受体: 7
• 质子供体: 3
• LogD (pH = 5.5): -2.5221028
• LogD (pH = 7.4): -0.91812485
• Log P: -0.57631254
• 摩尔折射率: 81.0675 cm^3
• 极化性: 30.825937 Å^3
• 极化表面积: 146.85 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true

分子性质

安全信息

• 保存条件: -20°C

药理学性质

• 生物活性机理: Aciclo-GTP is a very potent inhibitor of viral DNA polymerase; Prodrug of aciclovir.

产品相关信息

• 成盐信息: hcl; HCl
• 应用领域: Active against herpes simplex and herpes zoster (shingles), Varicella zoster virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV); Antiviral agent

详细说明

Selleck Chemicals - S1876

Research Area: Infection
Biological Activity:

参考文献

• Ger. Pat., 1976, 2 539 963; CA, 84, 180300p, (synth)
• Elion, G.B. et al., Proc. Natl. Acad. Sci. U.S.A., 1977, 74, 5716, (pharmacol)
• Fiddian, A.P., Appl. Virol., 1984, 103, (rev, pharmacol)
• Birnbaum, G.I. et al., Can. J. Chem., 1984, 62, 2646, (cryst struct)
• Krenitsky, T.A. et al., Proc. Natl. Acad. Sci. U.S.A., 1984, 81, 3209-3213, (synth, pharmacol)
• Krasny, H.C. et al., Biochem. Pharmacol., 1986, 35, 4339, (metab)
• Rees, P.J. et al., J. Antimicrob. Chemother., 1986, 18, 215-222, (pharmacokinet)
• Kelley, J.L. et al., J. Het. Chem., 1986, 23, 271, (synth)
• Chu, C.K. et al., J. Het. Chem., 1986, 23, 289, (rev)
• Radl, S. et al., Cesk. Farm., 1987, 36, 58, (synth)
• Petty, B.G. et al., Antimicrob. Agents Chemother., 1987, 31, 1317-1322, (pharmacokinet)
• Matsumoto, H. et al., Chem. Pharm. Bull., 1988, 36, 1153, (synth)
• Arndt, K.A. et al., J. Am. Acad. Dermatol., 1988, 18, 188, (adverse effects)
• Eur. Pat., 1989, Wellcome, 308 065; CA, 112, 112048j, (Valaciclovir)
• Stimac, A. et al., Synthesis, 1990, 461-464, (synth)
• Reardon, J.E. et al., Adv. Pharmacol., 1991, 22, 1, (rev)
• Alhede, B. et al., J.O.C., 1991, 56, 2139, (synth, cmr)
• De Miranda, P. et al., Antiviral Chem. Chemother., 1992, 3, 1, (metab, rev)
• Beauchamp, L.M. et al., Antiviral Chem. Chemother., 1992, 3, 157, (Valaciclovir)
• U.K. Pat., 1993, Norsk Hydro A/S, 2 260 319; CA, 119, 271633g, (acyclovir elaidate)
• De Miranda, P. et al., Drug Metab. Dispos., 1994, 22, 55, (Valaciclovir)
• Wagstaff, A.J. et al., Drugs, 1994, 47, 153, (rev)
• Buck, I.M. et al., Tetrahedron, 1994, 50, 9195-9206, (synth)
• Shinkai, I. et al., Bioorg. Med. Chem., 1996, 4, 1, (rev, Valaciclovir)
• Plass, M. et al., J.C.S. Perkin 2, 1999, 2641-2646, (uv, pmr, ir, Raman)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 602; 628
• Ormrod, D. et al., Drugs, 2000, 59, 839-863; 1317-1359
• Gao, H. et al., Synthesis, 2000, 329-351, (rev)
• Gao, H. et al., Synth. Commun., 2001, 31, 1399-1419, (synth)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AEC700; AEC725